Obesity Medicine Association's 2026 heart statement urges treating obesity first, and says it is not a guideline

The Obesity Medicine Association published a Clinical Practice Statement on obesity and cardiovascular disease on 5 June 2026, in the journal Obesity Pillars. It ran in the December 2026 print collection and was indexed in PubMed this week. It is a long document, 26 sections, and it sets out a position rather than reporting a new study.

The position is that obesity should be treated directly, and early, instead of only managing the conditions it produces. The authors call this treating obesity first.

Two ways excess fat is said to damage the heart

The statement separates the problem into two parts. The first it calls fat mass disease: the physical effects of carrying extra tissue, such as increased blood volume, thickening of the heart muscle under that load, impaired filling of the heart because of fat around it, and sleep apnea.

The second it calls sick fat disease, or adiposopathy: fat tissue that is not working properly and sends out inflammatory and hormonal signals. The authors argue that this pathway drives type 2 diabetes, high blood pressure, abnormal cholesterol and blood clotting, which in turn drive heart disease.

On measurement, the statement says body mass index is useful at a population level, but that percent body fat is a better way to judge how much fat tissue a person carries, and that fat around the organs in the abdomen is a better predictor of cardiovascular risk than BMI alone.

Which drugs the statement says have shown heart benefit, and which have not

The authors draw a clear line between medicines that have reduced cardiovascular events in trials and medicines that have only improved risk factors. As the statement summarizes those trials:

• Semaglutide reduced major adverse cardiovascular events by 20% in the SELECT trial, in people with overweight or obesity and existing heart disease.
• Tirzepatide reduced a combined measure of cardiovascular death or worsening heart failure in SUMMIT, in people with obesity-related heart failure with preserved ejection fraction. The benefit came mainly from fewer worsening heart failure events, with no significant difference in cardiovascular death on its own.
• Semaglutide improved symptoms in STEP HFpEF and protected kidney function in FLOW.
• Liraglutide at diabetes doses reduced major adverse cardiovascular events in LEADER. The authors note there is no equivalent trial for liraglutide at obesity doses.
• Phentermine, phentermine with topiramate, naltrexone with bupropion and orlistat produce modest weight reduction and improve some risk factors, but none has shown a definitive reduction in cardiovascular events.

The statement also puts a threshold on weight change: 5% to 10% reduction improves cardiometabolic risk factors, while reduction above 10% is more consistently linked to fewer cardiovascular events.

What it says about gastric bypass and sleeve gastrectomy

On surgery, the authors write that gastric bypass and sleeve gastrectomy have the most consistent long-term evidence of cardiovascular benefit, and that most of the documented risk reduction from bariatric surgery comes from studies of those two operations. They list lower long-term risk of heart attack, stroke, heart failure, atrial fibrillation, progression of chronic kidney disease and death from any cause.

Between the two, the statement says gastric bypass has the most extensive long-term data and better remission rates for type 2 diabetes and abnormal cholesterol, while sleeve gastrectomy reaches comparable metabolic improvement with a more favorable safety profile. Reflux is given as a deciding factor in choosing between them: sleeve gastrectomy can make reflux worse, while gastric bypass often improves it.

The risks are stated alongside. Nutritional deficiencies are described as common, particularly vitamin D, vitamin A, thiamine, folate, vitamin B12, calcium, magnesium, iron and zinc, often requiring lifelong supplementation and monitoring. The authors also note higher fracture risk and the possibility of reoperation, and say that long-term cardiovascular benefit depends on structured follow-up rather than the operation alone.

On combining approaches, the statement says obesity medications before surgery can reduce surgical risk, and medications after surgery can improve weight reduction and help maintain it.

Not a guideline, by the authors' own description

This matters for how much weight to give the document. The authors state directly that the Clinical Practice Statement is not a guideline, because it does not provide graded clinical recommendations. It is an expert review, and where the scientific data were inconclusive or insufficient, the authors say they applied their professional judgment.

That is a meaningful distinction. A graded guideline tells a reader how strong the evidence behind each recommendation is. This document does not, so a statement inside it may rest on large randomized trials or on the authors' reading of an unsettled literature, and the text does not always separate the two.

The disclosures are extensive. The lead author reports that his research institution has received grants from dozens of pharmaceutical companies, including several that make obesity medicines, and reports advisory roles with many of the same firms. The statement itself received no funding, and peer review was carried out by Obesity Medicine Association board members who were not authors.